Matt Davidson Buys Shares of Adial Pharmaceuticals

Matt Davidson, the Chief Development Officer at Adial Pharmaceuticals, Inc. (NasdaqCM: ADIL), recently purchased 1,923 shares of the company. This insider transaction took place on June 11, 2026, and was not part of a pre-planned purchase.

Insider Buying and Selling at Adial Pharmaceuticals, Inc.

Matt Davidson's recent purchase isn't his only transaction. On June 12, 2026, he also acquired 232,417 shares, while Wendy Young bought 36,378 shares at an average price of $2.75 on the same day. These transactions highlight ongoing insider interest in the company's stock.

Other Institutional Activity in Adial Pharmaceuticals

Institutional investors have also been active with Adial Pharmaceuticals. Geode Capital Management, LLC increased its stake by 18,019 shares, bringing its total to 24,249 shares worth about $43,405. Vanguard Fiduciary Trust Co added 5,879 shares, resulting in a total of 5,879 shares valued at approximately $10,523. Meanwhile, Tower Research Capital LLC (TRC) significantly increased its holdings by 1,302 shares, now holding 1,356 shares valued at $2,427.

Adial Pharmaceuticals Stock Snapshot

Shares of Adial Pharmaceuticals are trading around $2.85. The company, with a market cap of about $6.24 million, is not currently profitable, reflected in its negative forward P/E ratio. The stock has seen a 52-week range between $1.31 and $19.00. Its 50-day moving average stands at $1.87, while the 200-day moving average is $5.16. The company maintains a current ratio of 3.18, indicating its ability to cover short-term liabilities.

Analysts Set New Price Targets

Lucid Capital Markets initiated coverage on Adial Pharmaceuticals with a 'buy' rating and a price target of $6.00 on June 15, 2026. Previously, Maxim Group upgraded the stock to 'buy' with a target of $1.50 on September 30, 2025. The consensus recommendation is a 'buy', with a mean target price of $8.00 from one analyst opinion.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc. is a biotechnology company based in Glen Allen, Virginia. It focuses on developing treatments for addiction and related disorders. Its lead product, AD04, is in Phase 3 trials for treating alcohol use disorder. The company also explores drug candidates for non-opioid pain reduction and other conditions. Founded in 2010, Adial operates with a small team under CEO Mr. Cary John Claiborne.

Bottom Line

Matt Davidson's recent stock purchase at Adial Pharmaceuticals reflects insider confidence in the company. Investors often track insider activity for insights, though it's important to note that these transactions are reported after they occur. Adial Pharmaceuticals remains a company of interest due to its ongoing clinical trials and institutional investor activity.